Fiscal Year 2016: CDC's Division of Viral Hepatitis supported funding 54 grantees to conduct hepatitis prevention and surveillance activities as well as a several educational projects and projects that identify and screen chronically infected hepatitis B and C patients and link them to care.
Fiscal Year 2017: CDC's Division of Viral Hepatitis supports funding 50 grantees to conduct hepatitis prevention and surveillance activities as well as a several educational projects and projects that identify and screen chronically infected hepatitis B and C patients and link them to care.
Fiscal Year 2018: CDC's Division of Viral Hepatitis is anticipating funding 50 grantees to conduct hepatitis prevention and surveillance activities as well as a several educational projects and projects that identify and screen chronically infected hepatitis B and C patients and link them to care.
The Department of Health and Human Services is the Federal government's principal agency for protecting the health of all Americans and providing essential human services, especially to those who are least able to help themselves.
Fiscal Year 2016: Funds were provided for hepatitis B and C testing and linkage to care activities, and to characterize the hepatitis C increase among injection drug users as well as continued support for viral hepatitis surveillance, prevention and education. Fiscal Year 2017: CDC's Division of Viral Hepatitis anticipates funding will continue to be provided for hepatitis B and C testing and linkage to care activities, and to characterize the hepatitis C increase among injection drug users as well as continued support for viral hepatitis surveillance, prevention and education. Fiscal Year 2018: Funding will continue to be provided for hepatitis B and C testing and linkage to care activities, and to characterize the hepatitis C increase among injection drug users as well as continued support for viral hepatitis surveillance, prevention and education.
Uses and Use Restrictions
Funds may be used for costs associated with establishing and maintaining a prevention and control program directed towards prevention of viral hepatitis infections and their manifestations.
Recipients may only expend funds for reasonable policies, systems and program purposes including personnel, travel, supplies and services, such as reducing transmission of HAV, HBV and HCV, preventing and delaying the progress of chronic infection, as well as educating and training of the general public and health care providers.
Recipients may not use funds for clinical care.
Recipients may not generally use funding for the purchase of furniture or equipment.
Any such proposed spending must be identified in the budget.
The recipient must perform a substantial role in carrying out project objectives and not merely serve as a conduit for an award in another party or provider who is eligible.
Applicants include State or local governments or their Bona Fide Agents, public and private nonprofit organizations, for profit organizations, small, minority, women-owned businesses, universities, colleges, research institutions, hospitals, community-based organizations, faith based organizations, Federally recognized Indian tribal governments, Indian tribes, and Indian tribal organizations.
Additional guidance may be provided in individual program.
The individual will benefit from the objectives of this program as well as the community at large, and society from the savings realized from treating those who are infected with viral hepatitis.
No Credentials or documentation are required. This program is excluded from coverage under 2 CFR 200, Subpart E - Cost Principles.
Aplication and Award Process
Preapplication coordination is not applicable.
Environmental impact information is not required for this program.
This program is eligible for coverage under E.O.
12372, 'Intergovernmental Review of Federal Programs.' An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review.
2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. OMB Circular No. A-102 applies to this program. OMB Circular No. A-110 applies to this program. Applicants must download application forms from www.Grants.gov. Applications must be submitted electronically at www.Grants.gov. If an applicant does not have access to the Internet, or if they have difficulty accessing the forms on-line, contact the CDC Office of Grant Services Technical Information Management Section (OGS-TIMS) staff. For this, or further assistance, contact OGS-TIMS: Telephone (770) 488-2700, Email: firstname.lastname@example.org.
Successful applicants will receive a Notice of Award (NoA) from the CDC Office of Grants Services. The NoA shall be the only binding, authorizing document between the recipient and CDC. The NoA will be signed by an authorized Grants Management Officer and emailed to the program director, and a hard copy mailed to the recipient fiscal officer identified in the application.
Contact the headquarters or regional office, as appropriate, for application deadlines.
Sections 301 and 317K(k)(2) of the Public Health Service Act (42 U.S.C. section 241 and 274b-15), as amended.
Range of Approval/Disapproval Time
From 120 to 180 days. Deadline for submission of applications will be between 30-60 days from date of publication.
Renewals will be based upon the conditions in the notice of funding opportunity (NOFO) and are subject to the availability of funds.
Formula and Matching Requirements
This program has no statutory formula. Matching requirements are not applicable to this program. This program does not have MOE requirements.
Length and Time Phasing of Assistance
Project period is for 2-5 years with 12-month budget period. See the following for information on how assistance is awarded/released: Assistance is awarded through Notice of Grant Awards (NoAs) to funded applicants. See the following for information on how assistance is awarded/released: Award through a Notice of Grant Award.
Post Assistance Requirements
Program reports are due annually.
Also see NOFO for additional information.
Programs are required to report carryover funds annually through form SF-51.
Progress reports are due and must outline how the grantee is meeting the objectives as outlined in the NOFO.
A form SF-51 is required annually.
Yes, as part of progress report, and rapid feedback reports are part of the process for monitoring.
In accordance with the provisions of 2 CFR 200, Subpart F - Audit Requirements, non-Federal entities that expend financial assistance of $750,000 or more in Federal awards will have a single or a program-specific audit conducted for that year. Non-Federal entities that expend less than $750,000 a year in Federal awards are exempt from Federal audit requirements for that year, except as noted in 2 CFR 200.503. In addition, grants and cooperative agreements are subject to inspection and audits by DHHS and other Federal officials.
Financial records, supporting documents, statistical records, and all other reports pertinent to the program shall be retained for a minimum of 3 years, or until completion and resolution of any audit in process or pending resolution. In all cases, records must be retained until resolution of any audit questions. Property records must be retained in accordance with 45 CFR 92.42.
75-0950-0-1-550 - Prevention Effectiveness, HIV/AIDS,Viral Hepatitis, Sexually Transmitted Diseases and Tuberculosis Prevention; 09-2950-2-0-131 - Direct Category A funding: Viral Hepatitis;.
(Cooperative Agreements) FY 16 $16,815,000; FY 17 est $16,409,000; and FY 18 est $16,409,000
Range and Average of Financial Assistance
Awards will range from approximately $30,000 to $500,000, with an average award of $150,000.
Regulations, Guidelines, and Literature
Regional or Local Office
None. Viral Hepatitis Program Contact: Jeffrey L. Efird, MPA, Deputy Director, Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Department of Health and Human Services, 1600 Clifton Rd. NE, Mailstop G-37, Atlanta, GA 30333. E-mail: email@example.com. Grants Management Contact: Carla Harper, Grants Management officer, Department of Health and Human Services, CDC Procurement and Grants Office, 2920 Brandywine Road, MS E-15, Atlanta, GA 30341, telephone 770-488-2439, E-mail: CHarper@cdc.gov.
Elizabeth Wolfe 1600 Clifton Road, NE, Mailstop E-07, Atlanta, Georgia 30333 Email: firstname.lastname@example.org Phone: (404) 639-8531
Criteria for Selecting Proposals
Applications will be reviewed for completeness by the Office of Grants Services (OGS) staff and for responsiveness jointly by Division of Viral Hepatitis (DVH), NCHHSTP. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance through the review process. Applicant will be notified that the application did not meet submission requirements. CDC will conduct a review to evaluate complete and responsive applications according to the criteria listed in Section V. Application and Submission information, subsection ?Evaluation Criteria? within the individual funding opportunity announcement.
Kavita Shukla founded Fenugreen, a social enterprise established at addressing global food supply spoilage with a simple innovation, Freshpaper, a paper infused with edible, organic botanical extracts, a product inspired by her grandmother.
Unable to select database